BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33393047)

  • 1. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation.
    Sekigami Y; Michelakos T; Fernandez-Del Castillo C; Kontos F; Qadan M; Wo JY; Harrison J; Deshpande V; Catalano O; Lillemoe KD; Hong TS; Ferrone CR
    Ann Surg Oncol; 2021 Aug; 28(8):4592-4601. PubMed ID: 33393047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
    Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
    Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
    Kang JH; Lee SS; Kim JH; Byun JH; Kim HJ; Yoo C; Kim KP; Ryoo BY; Kim SC
    Eur Radiol; 2021 Feb; 31(2):864-874. PubMed ID: 32813104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
    Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
    J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
    Janssen QP; van Dam JL; Prakash LR; Doppenberg D; Crane CH; van Eijck CHJ; Ellsworth SG; Jarnagin WR; O'Reilly EM; Paniccia A; Reyngold M; Besselink MG; Katz MHG; Tzeng CD; Zureikat AH; Groot Koerkamp B; Wei AC;
    J Natl Compr Canc Netw; 2022 Jul; 20(7):783-791.e1. PubMed ID: 35830887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy.
    Michelakos T; Sekigami Y; Kontos F; Fernández-Del Castillo C; Qadan M; Deshpande V; Ting DT; Clark JW; Weekes CD; Parikh A; Ryan DP; Wo JY; Hong TS; Allen JN; Catalano O; Warshaw AL; Lillemoe KD; Ferrone CR
    J Gastrointest Surg; 2021 Nov; 25(11):2859-2870. PubMed ID: 33501584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
    Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
    Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
    Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
    Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.
    Noda Y; Pisuchpen N; Mercaldo ND; Sekigami Y; Michelakos T; Parakh A; Wo JY; Qadan M; Ferrone C; Lillemoe KD; Ryan DP; Clark JW; Fernandez-Del Castillo C; Hong TS; Kambadakone AR
    Eur Radiol; 2022 Apr; 32(4):2470-2480. PubMed ID: 34665317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
    He J; Blair AB; Groot VP; Javed AA; Burkhart RA; Gemenetzis G; Hruban RH; Waters KM; Poling J; Zheng L; Laheru D; Herman JM; Makary MA; Weiss MJ; Cameron JL; Wolfgang CL
    Ann Surg; 2018 Jul; 268(1):1-8. PubMed ID: 29334562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
    van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
    JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
    Cecchini M; Miccio JA; Pahade J; Lacy J; Salem RR; Johnson SB; Blakaj A; Stein S; Kortmansky JS; Johung KL
    Pancreas; 2020 Aug; 49(7):904-911. PubMed ID: 32658074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
    Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
    Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.